c-Myc suppresses p21WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells.
about
The ability to generate senescent progeny as a mechanism underlying breast cancer cell heterogeneityAP4 encodes a c-MYC-inducible repressor of p21Estrogen regulation of cyclin E2 requires cyclin D1 but not c-MycExamination of the expanding pathways for the regulation of p21 expression and activity.Regulation of GREB1 transcription by estrogen receptor alpha through a multipartite enhancer spread over 20 kb of upstream flanking sequencesp21 in cancer: intricate networks and multiple activitiesPathways to tamoxifen resistance.ERRβ signalling through FST and BCAS2 inhibits cellular proliferation in breast cancer cells.Functional ablation of pRb activates Cdk2 and causes antiestrogen resistance in human breast cancer cellsIdentification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer.Regulation of hormonal therapy resistance by cell cycle machinery.Identification of miR-26 as a key mediator of estrogen stimulated cell proliferation by targeting CHD1, GREB1 and KPNA2.Partial inhibition of estrogen-induced mammary carcinogenesis in rats by tamoxifen: balance between oxidant stress and estrogen responsivenessPalbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.MYC and Breast Cancer.Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARγ-independent mechanismβ-catenin regulates c-Myc and CDKN1A expression in breast cancer cells.HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.By recruiting HDAC1, MORC2 suppresses p21 Waf1/Cip1 in gastric cancer.Altered regulation of PDK4 expression promotes antiestrogen resistance in human breast cancer cellsNuclear receptor hepatocyte nuclear factor 4alpha1 competes with oncoprotein c-Myc for control of the p21/WAF1 promoter.Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 InhibitorsThe estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome.Estrogenic or antiestrogenic therapies for multiple myeloma?Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.Progress with palbociclib in breast cancer: latest evidence and clinical considerations.Activation of VCAM-1 and its associated molecule CD44 leads to increased malignant potential of breast cancer cells.CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.Histone demethylase KDM5B collaborates with TFAP2C and Myc to repress the cell cycle inhibitor p21(cip) (CDKN1A).SCFFbl12 Increases p21Waf1/Cip1 Expression Level through Atypical Ubiquitin Chain Synthesis.A novel antioxidant 3-O-Caffeoyl-1-methylquinic acid enhances ultraviolet A-mediated apoptosis in immortalized HaCaT keratinocytes via Sp1-dependent transcriptional activation of p21(WAF1/Cip1).c-Myc mediates pre-TCR-induced proliferation but not developmental progressionSOCS3 regulates p21 expression and cell cycle arrest in response to DNA damage.Reduced expression of ubiquitin ligase FBXW7 mRNA is associated with poor prognosis in breast cancer patients.ERβ alters the chemosensitivity of luminal breast cancer cells by regulating p53 function.
P2860
Q21136336-D8678A3C-23AA-4969-B473-489E62669789Q24316196-82572223-8D69-4894-9D08-600749314F3CQ24653031-FAC40234-397C-43C6-8372-276927E9EA15Q27692024-2336369F-0F5D-4D3C-ADDF-6F345CFB8B1AQ28299630-CE52578F-DC01-4A6A-8262-E65C5AF989B7Q30436015-D21E9034-CAF3-4254-BB28-1372E45F8FB2Q30441001-59FC3768-D8FC-4C5A-8B91-09F0F97158B9Q30576405-4A325BB1-4D31-4D3A-8921-5291FF02626DQ33308716-DA119E83-50EA-4430-8098-D5FA79F6B970Q33361574-A2007BDB-DF1C-4783-8D9D-A59A5C1780C2Q33635621-FA006259-E4D9-46B9-A2BE-51357141C4CEQ33739866-58A2D3E6-5458-4A43-A238-E09A343A6101Q34038020-FA316EBC-8846-4BDF-97CF-DE685687FD50Q34394399-69D8CABC-A834-4A30-968B-73BB59881B20Q34972381-4F5ED429-E696-4331-BED3-9EE6BFC8E7A3Q35124419-EA9E734E-2B9E-41B1-85A0-4FE760E3811AQ35930626-8DBB436E-469F-4430-825E-641CC89EF396Q36029524-97BFB413-8B0F-4112-8026-55D26A495472Q36140839-3108C213-BD30-4B65-807F-351F47F3896BQ36269713-66568BA6-6DE5-4FDF-AA3C-6CBDF4CA1C90Q36372654-D5BD459B-5375-436A-9867-E3C3299572CAQ36420373-6F15FE5D-61E0-4B9B-9363-A0435E024E79Q36678674-1AF7D8D9-3EDE-40AE-9909-8BFEF3FA7C71Q36948728-6B1CA5A1-F41F-42E5-BE6F-7C27C7972137Q37520483-E4DD93D3-E6B2-4DE0-A1A4-E8C21C59CB22Q37632170-D951757F-6B5E-4A93-9858-15B66A5B2F1DQ37683976-5383AB3A-9CD7-44B5-B7D3-10EE8A7DB93CQ38870640-A106F0B5-CFAA-4606-9684-DF8823B437B1Q39389047-23D8DA0C-11C9-49A2-9069-79CCB5F9971EQ39743125-AAD30D42-0168-4D0F-A826-CD661EE37D33Q40200601-179FB529-3E59-4EDC-8977-3C9169CE3F85Q42742027-3132AD04-110D-41F0-8D30-0869CADB4CF8Q43135527-2F89B2E4-D1CB-4AA4-8D80-5C0A88012F81Q53285198-6B46D0C1-79C7-4F77-A10E-19F1D09CAE06Q55421291-06A39351-FB25-4A9C-88F7-273B605B2999
P2860
c-Myc suppresses p21WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
c-Myc suppresses p21WAF1/CIP1 ...... in human breast cancer cells.
@en
type
label
c-Myc suppresses p21WAF1/CIP1 ...... in human breast cancer cells.
@en
prefLabel
c-Myc suppresses p21WAF1/CIP1 ...... in human breast cancer cells.
@en
P2860
P356
P1476
c-Myc suppresses p21WAF1/CIP1 ...... in human breast cancer cells.
@en
P2093
Shibani Mukherjee
Susan E Conrad
P2860
P304
17617-17625
P356
10.1074/JBC.M502278200
P407
P577
2005-03-08T00:00:00Z